Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTGFRN CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Osaka University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral
01
Overview
PTGFRN CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy targeting Prostaglandin F2 Receptor Negative Regulator (PTGFRN), a transmembrane protein in the tetraspanin family. PTGFRN is overexpressed on glioblastoma (GBM) tumor cells but absent in nonmalignant human brain tissue, making it a potential tumor-specific antigen. Developed by researchers at Osaka University and Osaka National Hospital, the therapy utilizes a CAR construct derived from a monoclonal antibody library (specifically clone 5E17) screened against patient-derived tumor spheres. In preclinical studies, these CAR-T cells have demonstrated significant antitumor activity, including increased production of IL-2 and IFN-γ and reduced tumor growth in orthotopic xenograft models of glioblastoma.
- Other names
- PTGFRN-targeted CAR-T cellsProstaglandin F2 receptor negative regulator CAR-T cells
02
Targets
PTGFRN
Beyond the preview
Go deeper on PTGFRN CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTGFRN CAR-T cells.